Re: AACR

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: AACR

in response to

Re: AACR

BearDownAZ

posted on Apr 08, 2019 11:46AM

Poster video summary by one of the lead investigators of the ZEN-3694/enzalutamide combo mCRPC trial, Dr. Rahul Aggarwal, from UCSF. Nice to hear someone other than Zenith speak highly of ZEN-3694.

https://twitter.com/UCSFCancer/status/1112782317783842816?s=20

"Encouragingly in this study we have many patients with durable disease stabilization lasting more than one year. The company is planning a follow on randomized Phase 2 study on the basis of these results..........We plan to present these results in more detail at a future meeting."

Perhaps Zenith will present these in more detail at the upcoming American Society for Clinical Oncology (ASCO) meeting May 31 to June 4, 2019? It's on the Zenith schedule of events, but I couldn't find any abstract/presentation listing for Zenith.